Thiazole Antibiotic Thiostrepton Synergize with Bortezomib to Induce Apoptosis in Cancer Cells by Pandit, Bulbul & Gartel, Andrei L.
Thiazole Antibiotic Thiostrepton Synergize with
Bortezomib to Induce Apoptosis in Cancer Cells
Bulbul Pandit
1, Andrei L. Gartel
1,2,3*
1Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America, 2Department of Biochemistry and Molecular Genetics, University of
Illinois at Chicago, Chicago, Illinois, United States of America, 3Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois, United
States of America
Abstract
Thiazole antibiotic, thiostrepton was recently identified as proteasome inhibitor. We investigated the therapeutic potential
of the combination of thiostrepton and proteasome inhibitor bortezomib (Velcade) on various human tumor cell lines.
Combination of sub-lethal concentrations of thiostrepton and bortezomib induced potent apoptosis and inhibition of long-
term colony formation in a wide variety of human cancer cell lines. The synergistic relationship between thiostrepton and
bortezomib combination was also quantitatively demonstrated by calculating their combination index values that were
much lower than 1 in all studied cell lines. The synergy between these drugs was based on their proteasome inhibitory
activities, because thiostrepton modification, thiostrepton methyl ester, which did not have intact quinaldic acid ring and
did not inhibit proteasome activity failed to demonstrate any synergy in combination with bortezomib.
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Introduction
Combination of targeted drugs/agents has received a consensus
as a viable potential strategy for the treatment of malignancy.
Treatment with a conjunction of agents that target key cellular
mechanism or proteins critical for various cancers are being
investigated against a variety of tumors. Combination of drugs
allows for their use at subtoxic concentrations and decreases the
likelihood of development of resistant cancer cells.
The proteasome is a protein complex that target ubiquitin-
tagged proteins for degradation in an ATP-dependent manner.
Recent advances in the understanding of the mechanisms of
proteasome activity led to the development of proteasome
inhibitors as effective drugs against human cancer [1]. Since
certain types of cancer rely on a functional proteasome for growth,
inhibition of proteasome activity would selectively kill these
tumors. Bortezomib (Velcade) is one of the first in class
proteasome inhibitors that inhibits the 26S proteasome by binding
to the N terminal threonine residues in the active site of the
proteasome catalytic region. It is approved for clinical use in cases
of relapsed multiple myeloma, but has demonstrated little to no
activity for treatment of solid tumors as a single agent. However,
by inhibiting the proteasome pathway and subsequent effect of
important pathways, bortezomib demonstrates synergistic rela-
tionship when combined with other anti-cancer drugs and
enhances the efficacy of drugs against malignancy.
In our previous studies we demonstrated that thiazole antibiotics
Siomycin A and thiostrepton induce apoptosis in human cancer
cells [2,3] and act as proteasome inhibitors [4]. It has been
demonstrated before that combination of two proteasome
inhibitors lactacystin and MG132 synergized against prostate
cancer cells in vitro [5]. Additionally, synergy was demonstrated
by combining bortezomib with curcumin (which demonstrates
proteasomal inhibitory activity in addition to other effects) against
multiple myeloma cells [6]. Similarly, we have demonstrated that
combination of thiostrepton and bortezomib demonstrated strong
synergy against prostate cancer [7]. In this study we confirmed
that co-treatment of various tumor cell lines of different origin with
sub-lethal concentrations of proteasome inhibitors thiostrepton
and bortezomib reveals a strong synergy as demonstrated by
induction of apoptosis, combination index values and long-term
clonogenic assay.
Results and Discussion
We showed earlier that proteasome inhibitor thiostrepton
inhibited the growth of various cancer cell lines with IC50 values
of (1–5 mM/L) and induced apoptosis [2,3]. Bortezomib has been
demonstrated to inhibit the viability of tumor cell lines with IC50
value of 10–100 nM/L. To determine whether thiostrepton may
synergize with bortezomib against human cancer cell lines of
different origin we treated multiple human cancer cell lines with
either sub-apoptotic concentrations of thiostrepton or bortezomib
alone or with combinations of the two for 24 hours and used
caspase-3 to serve as an indicator of apoptotic cell death (Figure 1).
While treatment with thiostrepton or bortezomib alone induced
little or no caspase-3 cleavage in these cells, treatment with
combination of these drugs showed potent caspase-3 cleavage in
U2OS-C3 osteosarcoma, MiaPaca-2 pancreatic, PA-1 ovarian,
HCT116 colon and MDA-MB-231 breast cancer cells (Figure 1),
and levels of apoptosis inversely correlated with FoxM1 expression
(Figure S1). Since we established earlier synergy between
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current data suggest that this effect may have general importance
for cancer treatment.
To further demonstrate that combination treatment of thios-
trepton and bortezomib induces synergistic apoptosis, we stained
these cells (DMSO treated, thiostrepton treated, bortezomib
treated and treated together with the two drugs) with annexin
V-PE/7AAD and analyzed them by flow cytometry. As shown in
Figure 2A, treatment of HCT-116 cells with 0.75 mM thiostrepton
or 10 nM bortezomib induced apoptosis of only 6.1% and 6.9%
over the control, while treatment with both drugs at the same
doses caused 35.2% of cells to undergo apoptosis. Similar
synergistic effect of thiostrepton/bortezomib combination was
observed by annexin-VPE-7AAD staining in MDA-MB231 breast
and MiaPaca-2 pancreatic cancer cells (Figure 2B and C).
To quantitatively validate the synergistic nature of the interaction
between thiostrepton and bortezomib, we examined cell viability
after single and combination drug treatments by using the Chou-
Talalay median-effect equation method [8]. CI values below 1
indicate a synergistic anti-proliferative effect, and the CI range
values for the combined treatments with thiostrepton/bortezomib
in HCT-116, Mia-Paca-2, MDA-MB231 and PA-1 human cancer
cell lines were 0.1 to 0.8 (Figure 3A, B, C, D) for fractional effect
corresponding to 0.3 to 0.9, suggesting a strong synergistic effect.
The long-term effects of combination treatment with thiostrepton
and bortezomib were assessed by clonogenic assay. We found that
colony formation in HCT-116 colon and MDA-MB 231 breast
cancer cells treated with combination of these drugs for 24 hours
was suppressed 5- to 10-fold (Figure 4A and B).
Following the demonstration of synergy between thiostrepton and
bortezomib combination, the significance of proteasomal inhibitory
activity of thiostrepton utilized in the combination was investigated.
The activity of the combination of thiostrepton methyl ester (open
ring inactive structural analog of thiostrepton) and bortezomib
combination was compared to thiostrepton and bortezomib. It was
demonstrated previously that an intact quinaldic acid macrocycle
ring in thiostrepton is required for proteasome inhibitory activity of
the thiazole antibiotics [9]. Absence of this ring or presence of an
open ring rendered the molecule inactive [10]. In contrast to
combination of thiostrepton/bortezomib, bortezomib and thios-
trepton methyl ester failed to demonstrate induction of apoptosis,
confirming the significance of proteasome inhibitory activity of
thiostrepton utilized in the drug combination (Figure 5). Some
studies have demonstrated a synergy following co-treatment with
proteasome inhibitors, lactacystin and MG132 [5], botezomib and
curcumin[6]againstcancer.Inthisstudyusingdifferentmethodswe
report that thiostrepton synergizes with bortezomib following co-
treatment with sub-lethal concentrations of the two agents,
suggesting that the combination of two proteasome inhibitors to
be of potential value as a general strategy against cancer.
Materials and Methods
Cell lines and reagents
U2OS-C3 osteosarcoma, HCT116 colon, PA1 ovarian and
MiaPaca-2 pancreatic cancer cells were cultured in DMEM medium
(Invitrogen). MDA-MB231 cells were grown in RPMI-1640 medium
(Invitrogen). The media were supplemented with 10% fetal bovine
Figure 1. Combination treatment of thiostrepton and bortezomib is synergistic in inducing apoptosis in tumor cells. A.
Osteosarcoma, U2OS-C3, B. MiaPaca-2 pancreatic, C. PA-1 ovarian, D. HCT-116 colon, E. MDA-MB-231 breast cancer cells were treated with sub-
apoptotic concentrations of thiostrepton, bortezomib or both as shown for 24 hrs, total cell lysates were extracted and immunoblotted with
antibodies for cleaved caspase-3 and b-actin.
doi:10.1371/journal.pone.0017110.g001
Synergy between Thiostrepton and Bortezomib
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and the cells were kept at 37uCi n5 %C O 2. Cell lines were tested for
mycoplasma contamination using MycoAlert Mycoplasma detection
kit (Lonza Rockland) and were found to be negative. Thiostrepton
was purchased from Sigma, bortezomib was kindly provided by
Millennium pharmaceuticals/Takeda. Open ring analog of thios-
trepton, thiostrepton methyl ester was kindly provided by Drs. Walsh
and Bowers (Harvard University).
Combination index assay
MTT assay was performed to measure the viability of cells
following treatment with single agents or combination of
thiostrepton and bortezomib. Each experiment involved treatment
with various concentrations of thiostrepton, bortezomib, combi-
nation of thiostrepton and bortezomib and a no drug treatment.
Additionally, the highest concentrations of thiostrepton, bortezo-
mib and the drug combination were tested in the absence of cells
and did not demonstrate any interference with the MTT assay
reagents.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) was procured from Sigma. Cells were plated at a density of
1610
4 per well in 200 mL of complete culture medium and treated
with thiostrepton alone, bortezomib alone and combination of
thiostrepton and bortezomib in 96-well micro titer plates. After
incubation for 72 hours at 37uC in a humidified incubator, 10 mL
MTT (5 mg/mL in PBS) was added to each well, following which
Figure 2. Combination treatment of thiostrepton and bortezomib is synergistic in inducing cell death in tumor cells. A. HCT-116,
colon, B. MDA-MB-231, breast and C. MiaPaca-2, pancreatic cancer cells treated with sub-apoptotic concentrations of thiostrepton, bortezomib and
thiostrepton/bortezomib combination for 24 hrs, stained with AnnexinV-PE and 7-AAD and analyzed by flow cytometry.
doi:10.1371/journal.pone.0017110.g002
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medium, 0.1 mL buffered DMSO was added to each well. The
absorbance was recorded on a micro-plate reader at the
wavelength of 540 nm. In our experiments, the IC30,I C 50,I C 70,
IC80, and IC90 values (i.e., the drug concentration needed to cause
30%, 50%, 70%, 80%, and 90% reductions in cell viability) were
chosen for comparison.
To evaluate the effect of combination treatment with thios-
trepton and bortezomib, the combination index (CI) isobologram
method of Chou and Talalay was used [8]. This method involves
plotting dose–effect curves for each agent and combinations in
multiple diluted concentrations by using the median–effect
equation and the combination index equation. Combination
index values of 1, ,1, and .1 indicate an additive effect,
synergism, and antagonism, respectively. The combination index
values were determined at different effect levels, and the
isobolograms plotted.
Detection of apoptosis
The AnnexinV-PE staining kit (Roche Diagnostic Corp.) was
used for the detection of apoptotic bodies following the vendor’s
protocol. This kit uses a dual-staining protocol in which the cells
show fluorescence of Annexin V (apoptotic cells) and fluorescence
of 7AAD (necrotic cells or late apoptotic cells). Briefly the tumor
cells were grown at a density of 50% confluence in 100-mm
culture dishes and were treated with varying concentrations of the
drugs for 24 hours. The cells were trypsinized, washed with PBS,
and were processed for labeling with annexinV-7AAD. The
labeled cells were analyzed by flow cytometry.
Immunoblotting
Actively dividing cells were seeded into a 100 mm plate at a
density of 7.5610
5 cells. Cells were treated with bortezomib alone,
thiostrepton alone and combination of thiostrepton and bortezo-
mib for 24 hours following which the cells were lysed. Cells were
lysed in IP buffer (20 mM HEPES, 1% Triton X-100, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 100 mM NaF, 10 mM
Na4P2O7, 1 mM sodium orthovanadate, 0.2 mM PMSF supple-
mented with protease inhibitor tablet (Roche Applied Sciences)
and the protein concentration was determined using the Bio-Rad
protein assay reagent. Fifty micrograms of the cell lysates were
separated by electrophoresis on SDS-polyacrylamide mini gel and
transferred to PVDF membrane. Immunoblotting was performed
with specific antibodies for cleaved caspase-3 (9664 cell signaling),
FoxM1 (kind gift from Dr. Costa’s lab) and b-actin (A5441,
Sigma).
Nuclear-ID Green Chromatin Condensation detection
Cells were stained using in vitro apoptosis detection kit (Cat#
ENZ-51021-K200 Enzo Life Sciences), according to the manu-
Figure 3. Combination of thiostrepton and bortezomib is synergistic in inhibiting proliferation in cancer cells. Combination index
chart for the thiostrepton/bortezomib drug combination was plotted with CI on y axis and fractional effect (FI) on x-axis. Percentage inhibition of
proliferation was determined following treatment with a single agent or the thiostrepton/bortezomib combination. Combination index (CI) values of
the two agents plotted for HCT-116 (A), Miapaca-2 (B), MDA-MB231 (C) and PA-1 ovarian cells (D).
doi:10.1371/journal.pone.0017110.g003
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bortezomib. A. Clonogenic assay of HCT-116 cells treated with DMSO or thiostrepton/bortezomib combination for 24 hrs as detailed; a photograph
of petri-dishes in a representative experiment is shown. B. Clonogenic assay of MDA-MB231 cells treated with DMSO or thiostrepton/bortezomib
combinations for 24 hrs.
doi:10.1371/journal.pone.0017110.g004
Figure 5. Thiostrepton with intact B ring potentiates chromatin condensation in vitro detection kit. Treatment with combination of
thiostrepton/bortezomib results in appearance of sub-G0 peak which reduces the fluorescence intensity in HCT-116 cells as opposed to untreated
control cells due to fragmentation of chromatin. The shift of the FI was comparable to the positive control provided in the kit (Staurosporine, data not
shown). Thiostrepton-methyl ester with open B ring does not affect the fluorescence intensity as opposed to untreated (control) cells.
doi:10.1371/journal.pone.0017110.g005
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5 cells were plated in
60 mm culture dishes and allowed to grow overnight. Cells were
treated with the sub-lethal concentrations of thiostrepton,
bortezomib or thiostrepton methyl ester or combination of
thiostrepton and bortezomib and thiostrepton-methyl ester and
bortezomib. Following overnight incubation of drugs cells were
trypsinized and submitted for flow cytometry analysis. Analysis
was done by using FL-1 channel of flow cytometer with excitation
wavelength of 488 nM. Staurosporine, provided in the kit was
used as a positive control.
Clonogenic survival assay
HCT-116 and MDA-MB231 cells were plated to medium plates
at 3610
5 cells confluence and treated with combination of
thiostrepton and bortezomib for 24 hrs. The cells were then
trypsinized, re-suspended in the media and counted. The cells
were re-seeded (750 cells per medium plate) and incubated for 10
days. Fresh media was added on the fifth day. On the tenth day,
media was removed from the dishes and washed once with ice-cold
PBS. The colonies were stained with 2 mls each of 0.25% 1, 9-
dimethyl-methylene blue in 50% ethanol for 45 minutes on a
rocking platform. The dishes were rinsed three times with PBS and
air-dried, and the colonies were counted.
Statistical analysis
Statistical analysis was performed with Microsoft Excel using
the Student t test. P values of ,0.05 were considered to be
statistically significant.
Supporting Information
Figure S1 Relative levels of FoxM1 may affect the
sensitivity to thiostrepton/bortezomib combination
treatment in human cancer cells. U2OS-C3 osteosarcoma
and MIA PaCa-2 pancreatic cancer cells were treated with DMSO
or indicated concentrations of thiostrepton and borteozomib
together for 24 hours. Cell lysates were immunoblotted for
FoxM1, cleaved caspase-3 and b-actin as the loading control.
(TIF)
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